Crossing borders: the need for empirical evidence of real-world evidence transportability in oncology
Plain language summary: What is this article about? This article discusses the challenges of using non local real-world evidence (RWE) in health technology assessments (HTA) when local data are unavailable, insufficient, or inappropriate. HTA organizations often prefer data collected locally or...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2025-07-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Plain language summary:
What is this article about? This article discusses the challenges of using non local real-world evidence
(RWE) in health technology assessments (HTA) when local data are unavailable, insufficient, or
inappropriate. HTA organizations often prefer data collected locally or regionally, but the lack of suitable
data in many markets has increased interest in understanding data ‘transportability’ – whether data from
one country or population can be used to predict outcomes in another. Established in 2024, the Flatiron
Fostering Oncology RWE Use Cases and Methods (FORUM) research consortium is exploring when and
how non-local RWE can be effectively applied, with initial work focused on lung cancer, breast cancer and
multiple myeloma.
What does the evidence suggest so far? Initial studies suggest RWE from the US could predict outcomes
in other countries with proper adjustment for population and treatment differences. Recent research in
advanced non-small cell lung cancer demonstrated that adjusted US data provided comparable survival
to real observed outcomes in Canada and the UK. This limited evidence base indicates that non-local RWE
can help inform decision-making when local data is unavailable.
What studies are needed next? The FORUM consortium is expanding research to other cancer types and
countries to better understand RWE transportability. Future studies will focus on comparing outcomes
across diverse healthcare systems, identifying key variables for adjustment and developing guidelines for
when and how non-local data can be used. These efforts aim to create a framework for the use of global
RWE in oncology HTA decision-making. |
|---|---|
| ISSN: | 2042-6313 |